Snapshot from Jun 25, 2026 at 22:38 UTC. For live data and tracking: View Live
Entities / Apalutamide
Other

Apalutamide

Tracked across 1 events · 6 articles · First seen May 31, 2026 · Last active Jun 02, 2026

Sentiment
80
Attention
6
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the NewsDesk Dashboard
Events (1)
6 80
Tech
J&J Erleada improves prostate cancer outcomes
Johnson & Johnson>>>'s prostate cancer drug, Apalutamide>>>, in combination with hormone-blocking therapy, has shown significant success in late-stage clinical trials. The study, presented at the American Society of Clinical Oncology>>> meeting, revealed that the regimen…
Impact: Apalutamide, a drug by Johnson & Johnson>>>, demonstrated improved efficacy in treating high-risk localized prostate cancer, leading to potential global regulatory approvals and increased usage.
May 31, 2026 · 6 articles
Key Actions (1)
95 Apalutamide reduced riskJ&J Erleada improves...
NEWSDESK
Track Apalutamide live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.